1 / 14

New projects FP5 - Key Action 3

New projects FP5 - Key Action 3. New projects FP 5 In Key Actions 1, 3, 4 and Generic Activities Following 2nd call for proposals (April 2000) Selection only Word file available from IVTIP Secretariat. New projects FP 5 - KA3 (1).

fawzi
Download Presentation

New projects FP5 - Key Action 3

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. New projects FP5 - Key Action 3 • New projects FP 5 • In Key Actions 1, 3, 4 and Generic Activities • Following 2nd call for proposals (April 2000) • Selection only • Word file available from IVTIP Secretariat

  2. New projects FP 5 - KA3 (1) • Suppression of programmed cell death in industrial scale biological production systems • 36 months, 884.161 €, demonstration project, QLK3-2000-00076. Coordinator: Al-Rubeai. Industry: Lonza Biologics • objective: demonstrate increased cellular productivity with overexpression of anti-apoptosis genes

  3. New projects FP 5 - KA3 (2) • Screening assays for new bacterial inhibitors based on targets active in sepation • 36 months, 1.354.932 €, research projects.QLK3-2000-00079. Coordinator Vicente (Madrid), industry: Hoechst Marion Roussel • objective: select new antibacterial compounds through high throughput screening and rational drug design

  4. New projects FP5 - KA3 (3) • Cellular production of human recombinant collagens, gelatins, laminins and growth factors and their use in vascular grafts and other applications • 36 months, 1.787.281 €, research project. QLK3-2000-00084. Coordinator: Taina Pihlajaniemi. Industry: Fibrogen Europe (Oulou) • objective: cost-effective recombinant collagen production applicable to several human collagens

  5. New projects FP5 - KA3 (4) • Evolutionary discovery of novel drugs by orchestration of polymer-supported combinatorial bio/chemistry • 36 months, 2.161.033 €, research project. QLK3-2000-00160. Coordinator: Udo Kragl. Industry: Polymer Laboratories UK, Morphochem (DE) • objective: synthesis of novel chemo- and biocatalytic combinatoprial libraries which will be screened for biological activities (antibacterial, anti-cancer agents)

  6. New projects FP5 - KA3 (5) • From conopeptide scaffolds to analgesic leads • 36 months, 1.751.351 €. Research project. QLK3-2000-00204. Coordinator: Michael Fainzilber. Industry: Sigyn Pharmaceuticals (Israel), Syngenix (UK) • objective: novel selection systems in yeast and mammalian cells to allow functional selection of novel conopeptide ligands

  7. New projects FP5 - KA3 (6) • Functional characterisation of orphan G-protein-coupled receptors and their validation as drug targets • 36 months, 1.484.368 €, research project. QLK3-2000-00237. Coordinator: Marc Parmentier (Be). Industry: Pharis Biotec (DE), Euroscreen (Be) • objective: in-depth study of natural ligands of 6 orphan receptors and their validation as targets for drug development

  8. New projects FP5 - KA3 (7) • Human cell systems for predicting allergenicity of genetically engineered proteins • 36 months, 1.355.584 €, research project. QLK3-2000-00270. Coordinator: Carl Borrebaeck. Industry: Novo Nordisk Enzyme Business • objective: study human immune cell culture systems for their potential to discriminate between allergenic (IgE-producing) and non-allergenic geneticall modified proteins

  9. New projects FP5 - KA3 (8) • Therapeutic substances for in vivo targeted gene modification • 36 months, 1.991.617 €, research project. QLK3-2000-00634. Coordinator: Stefan Krauss (Nor). Industry: Link Technologies Ltd (Scot) • objective: develop a generally applicable technology for targeted gene conversion in vivo using novel bioactive molecules: Therapeutic Repair Oligomers (TROs)

  10. New projects FP5 - KA3 (9) • New systems of controlled gene expression for improved delivery of therapeutic substances • 36 months, 1.383.841 €, research project. QLK3-2000-00721. Coordinator: Anne-Catherine Prats(Inserm, Fr). Industry: Cistronics Cell Technology (CH); Millegen (Fr) • objective: to combine major aspects of gene regulation to develop viable expression tools for therapeutic applications: mRNA transcription, stability and translation (multicistronic concept)

  11. New projects FP5 - KA3 (10) • Aquaporin blockers for novel skin care products and diuretics • 36 months, 1.747.168 €, research project. QLK3-2000-00778. Coordinator: Peter Deen (NL); Industry: Beiersdorf (DE) • objective: development novel skin care products and diuretics on the basis of aquaporin (AQP) function. Test and screening systems in yeast and mammalian cells.

  12. New projects FP5 - KA3 (11) • The B-cell line DT40 as a genetic model and a substitute for animal research • 36 months, 1.390.300 €, research project. QLK3-2000-00785. Coordinator: Jean-Marie Buerstedde. Industry: Cistronics Cell Technology (CH) • objective: establish critical generic resources to make the DT40 cell line a model system for systematic analysis of gene and protein interactions and networks

  13. New projects FP5 - KA3 (12) • Exploitation of Streptomyces protein secretion for robust biopharmaceutical bioprocess development (area 3.3.) • 36 months, 2.027.286 €, research project. QLK3-2000-00122. Coordinator: Jozef Anne (Be). Industry: Eurogenetics (Be), Inbiotec (Es), Eurogentec (Be) • objective: develop a robust bioprocess to produce heterologous proteins of biopharmaceutical relevance based on the exploitation of Streptomyces lividans protein secretion is aimed

  14. New projects FP5 - KA3 (13) • 3.1. Improving the diagnostic and therapeutic arsenal for health care: • selection (incl. 1 project 3.3.): 19.417.922 € • total: 24.106.951 • 3.2. Improving environmental sustainability (predom. Environment): 8.070.316 € • 3.3. New biological and biotechnological products and processes for agro-industry, agrifood and high value added chemicals (plants): 17.948.296 € • Total Key Action 3: 42.862.562 €

More Related